Goodwin Procter advised PointClickCare Corp. on the deal. PointClickCare Corp. announced its acquisition of Patient Pattern. The combination of PointClickCare and Patient Pattern will further the companies’...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Flare Capital on the deal. Flare Capital announced its investment in Hospital for Special Surgery’s (HSS) $21 million Series A fundraising round to launch...
You must be a Standard 1 Year member to access this content.
Davis Polk advised Novo Nordisk on the deal while Goodwin Procter represented Forma Therapeutics. Novo Nordisk announced its approximately $1.1 billion acquisition of Forma Therapeutics. Under the...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Frazier Healthcare Partners on the deal. Frazier Healthcare Partners announced its definitive agreement with BD (Becton, Dickinson and Company) (NYSE: BDX) for BD to...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Apollo Intelligence on the deal. Apollo Intelligence announced its sale to Frazier Healthcare Partners. Apollo will continue to focus on elevating industry standards for...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Sichuan Kelun-Biotech Biopharmaceutical Co. on the deal. Sichuan Kelun-Biotech Biopharmaceutical Co. announced its exclusive license and collaboration agreement with Merck for ex-China development...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented the underwriters in the IPO while Goodwin advised PepGen. PepGen, Inc., a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with...
You must be a Standard 1 Year member to access this content.
Wachtell, Lipton, Rosen & Katz advised Regeneron on the deal, while Goodwin represented Checkmate Pharmaceuticals. Fried Frank acted as counsel to Centerview Partners, financial advisor to...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal while Goodwin Procter represented Amylyx Pharmaceuticals. Amylyx Pharmaceuticals, Inc. (“Amylyx”), a clinical-stage pharmaceutical company...
You must be a Standard 1 Year member to access this content.
Goodwin advised Generate Biomedicine on the deal. Generate Biomedicines announced its research collaboration agreement with Amgen (NASDAQ: AMGN) to discover and create protein therapeutics for five clinical...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Senti Biosciences, while Davis Polk advised Dynamics Special Purpose Corp. on the deal. Senti Biosciences (“Senti Bio”) announced its definitive business combination agreement with...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Aura Biosciences on the deal. Aura Biosciences, Inc. (Nasdaq: AURA) announced its initial public offering of 5,400,000 shares of common stock at a public...
You must be a Standard 1 Year member to access this content.
